Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Dec;27(12):1716-1717.
doi: 10.1016/j.cmi.2021.08.024. Epub 2021 Sep 8.

Repurposed drugs for COVID-19: threshold and proof requirements for trials

Mical Paul  1 , Andre C Kalil  2
Affiliations
Editorial

Repurposed drugs for COVID-19: threshold and proof requirements for trials

Mical Paul et al. Clin Microbiol Infect. 2021 Dec.
No abstract available

PubMed Disclaimer

Comment on

  • An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19.
    Ader F, Peiffer-Smadja N, Poissy J, Bouscambert-Duchamp M, Belhadi D, Diallo A, Delmas C, Saillard J, Dechanet A, Mercier N, Dupont A, Alfaiate T, Lescure FX, Raffi F, Goehringer F, Kimmoun A, Jaureguiberry S, Reignier J, Nseir S, Danion F, Clere-Jehl R, Bouiller K, Navellou JC, Tolsma V, Cabié A, Dubost C, Courjon J, Leroy S, Mootien J, Gaci R, Mourvillier B, Faure E, Pourcher V, Gallien S, Launay O, Lacombe K, Lanoix JP, Makinson A, Martin-Blondel G, Bouadma L, Botelho-Nevers E, Gagneux-Brunon A, Epaulard O, Piroth L, Wallet F, Richard JC, Reuter J, Staub T, Lina B, Noret M, Andrejak C, Lê MP, Peytavin G, Hites M, Costagliola D, Yazdanpanah Y, Burdet C, Mentré F; DisCoVeRy study group. Ader F, et al. Clin Microbiol Infect. 2021 Dec;27(12):1826-1837. doi: 10.1016/j.cmi.2021.05.020. Epub 2021 May 26. Clin Microbiol Infect. 2021. PMID: 34048876 Free PMC article. Clinical Trial.

References

    1. Ader F., Peiffer-Smadja N., Poissy J., Bouscambert-Duchamp M., Belhadi D., Diallo A., et al. An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19. Clin Microbiol Infect. 2021;27:1826–1837. - PMC - PubMed
    1. Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results N Engl J Med. 2020;384:497–511. - PMC - PubMed
    1. Horby P.W., Mafham M., Bell J.L., Linsell L., Staplin N., Emberson J., et al. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020;396:1345–1352. - PMC - PubMed
    1. Singh B., Ryan H., Kredo T., Chaplin M., Fletcher T. Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19. Cochrane Database Syst Rev. 2021 - PMC - PubMed
    1. Fiolet T., Guihur A., Rebeaud M.E., Mulot M., Peiffer-Smadja N., Mahamat-Saleh Y. Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis. Clin Microbiol Infect. 2021;27:19–27. - PMC - PubMed

Substances